Conference Proceeding
Yuswanto Setyawan
Abstract
Anemia contributes to the increase in cardiovascular risk, the need for hospitalization, the length of treatment and the decrease in the quality of life of chronic kidney diseases (CKD) patients. This study aims to determine hemoglobin (Hb), transferrin saturation (TS) and serum ferritin (SF) profile and quality of life in CKD patients undergoing routine hemodialysis. A descriptive analytical study was conducted on 222 CKD patients at Sanglah General Hospital in Denpasar from January to December 2018. Hemoglobin, TS, and SF data were obtained from medical records and quality of life was measured using Kidney Disease Quality of Life Short Form (KDQOL-SF) version 1.3. Data were presented as mean±standard deviation. Observations in the 1st, 4th, 7th, 10th, and 12th month demonstrate mean Hb (g/dL) of 10.83 ± 2.29, 11.04 ± 2.68, 10.81 ± 2.11, 10.73 ± 2.19 and 10.50 ± 2.70, respectively, mean TS (%) of 31.63 ± 12.92, 32.63 ± 14.20, 35.07 ± 16.21, 25.82 ± 11.51, 46.98 ± 29.00, respectively, and mean SF (ng/mL) of 908.53 ± 709.14, 752.19 ± 589.88, 796.33 ± 491.17, 393.31 ± 476.51, 178.70 ± 00.00, respectively. Quality of life in the 1st and 12th month were 59.19 ± 20.87 and 56.62 ± 21.44, respectively. Based on these results, Hb, TS, and quality of life in CKD patients undergoing routine hemodialysis tend to be decreased within one year. Discussion: Viral infections after TR may be responsible for severe complications. Periodic assessments infectious must be undertaken and the systematic screening of cancers. CMV infections can be easily avoided by prophylactic treatment.Prevention of CMV infection in organ transplant is now possible and effective, even if the implementing rules are still imperfectly codified and vary from one team to another. Probably prophylaxis, the efficacy is clearly demonstrated, will become the most used strategy and it will be practical as routine as prophylaxis of P. 16th World Nephrology Conference August 20-21, 2020 Webinar Biography Yuswanto Setyawan has completed his recidency in Internal Medicine, at the age of 36 years, at Sam Ratulangi University, Manado, Indonesia. He is currently enrolled at the Nephrology and Hypertension Subspecialty Program at the Faculty of Medicine-Udayana University/Sanglah Hospital, Denpasar, Bali, Indonesia